CDK4 and cancer: In sum, our metabolic and transcriptomic analyses have revealed that depletion or inhibition of CDK4/6 in cancer cells leads to de novo addiction to MYC, and, as likely downstream consequences, also to glutaminase and mTOR signaling, as well as to a compromised adaptation to hypoxia.